(Q35734045)

10 August 2017

1 reference

title

Safety of tumour necrosis factor-alpha antagonists (English)

1 reference

10 August 2017

0 references

Dinesh Khanna

1

1 reference

10 August 2017

Maureen McMahon

series ordinal

2

1 reference

10 August 2017

Daniel E Furst

series ordinal

3

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

27

1 reference

10 August 2017

5

1 reference

10 August 2017

307-324

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200427050-00003

10 August 2017

0 references

cites work

Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1

1 reference

12 December 2020

Effect of patient adherence to antiretroviral therapy on CD4+ cell count, HIV-1 RNA, and serum concentrations of tumor necrosis factor and its soluble receptors

1 reference

12 December 2020

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Regulation of COX-2 gene expression in rat uterus in vivo and in vitro

1 reference

12 December 2020

Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis

1 reference

12 December 2020

Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination

1 reference

12 December 2020

Molecular cloning and expression of a receptor for human tumor necrosis factor

1 reference

12 December 2020

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

1 reference

12 December 2020

Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).

1 reference

12 December 2020

Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis

1 reference

12 December 2020

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

1 reference

12 December 2020

The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

1 reference

12 December 2020

Viral pneumonia as a serious complication of etanercept therapy

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines

1 reference

12 December 2020

Drug-induced systemic lupus erythematosus associated with etanercept therapy

1 reference

12 December 2020

Tumour necrosis factor-alpha induces cyclo-oxygenase-2 gene expression in first trimester trophoblasts: suppression by glucocorticoids and NSAIDs

1 reference

12 December 2020

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

12 December 2020

Cytokines modulate preimplantation development and pregnancy

1 reference

12 December 2020

Prediction of pregnancy in infertile women with endometriosis

1 reference

12 December 2020

Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma

1 reference

12 December 2020

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

1 reference

12 December 2020

Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease.

1 reference

12 December 2020

The mode of action of cytokine inhibitors

1 reference

12 December 2020

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Kinetics of cytokine expression in mice with invasive aspergillosis: lethal infection and protection

1 reference

12 December 2020

Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations

1 reference

12 December 2020

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

1 reference

12 December 2020

Basic mechanisms in heart failure: the cytokine hypothesis

1 reference

12 December 2020

Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists

1 reference

12 December 2020

Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences

1 reference

12 December 2020

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

12 December 2020

A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

1 reference

12 December 2020

The pharmacokinetics of etanercept in healthy volunteers

1 reference

12 December 2020

Rheumatoid vasculitis following influenza vaccination

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

12 December 2020

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

1 reference

12 December 2020

Evaluation of nonspecific immunity and plasma levels of interferon-gamma, interleukin-6 and tumor necrosis factor-alpha in preeclampsia

1 reference

12 December 2020

Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis

1 reference

12 December 2020

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

1 reference

12 December 2020

Drug-induced systemic lupus erythematosus and TNF-alpha blockers

1 reference

12 December 2020

Cytokines in synovial fluid: II. The presence of tumour necrosis factor and interferon.

1 reference

12 December 2020

Anti-implantation effects of indomethacin and celecoxib in rats

1 reference

12 December 2020

Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons

1 reference

12 December 2020

Evolving concepts of rheumatoid arthritis

1 reference

12 December 2020

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

12 December 2020

Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis

1 reference

12 December 2020

Vaccination and rheumatoid arthritis

1 reference

12 December 2020

Pregnancy and exposure to infliximab (anti-tumor necrosis factor-alpha monoclonal antibody)

1 reference

12 December 2020

Cancer morbidity in rheumatoid arthritis

1 reference

12 December 2020

Tumor necrosis factor during pregnancy and at the onset of labor and spontaneous abortion

1 reference

12 December 2020

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

12 December 2020

Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH

1 reference

12 December 2020

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

12 December 2020

Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study

1 reference

12 December 2020

Infectious complications of biologic treatments of rheumatoid arthritis

1 reference

12 December 2020

Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum

1 reference

12 December 2020

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

1 reference

12 December 2020

Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents

1 reference

12 December 2020

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

12 December 2020

Mortality from cancer in patients with rheumatoid arthritis

1 reference

12 December 2020

Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.

1 reference

12 December 2020

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

1 reference

12 December 2020

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

12 December 2020

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis

1 reference

12 December 2020

Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

1 reference

12 December 2020

Infliximab in the treatment of an HIV positive patient with Reiter's syndrome

1 reference

12 December 2020

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

12 December 2020

10.2165/00002018-200427050-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

0 references

1 reference